The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Common Cancer-associated Antigens (CAAs) Vaccine-Global Market Insights and Sales Trends 2024
Synopsis
Perhaps a more cost-effective option lies in developing vaccines using common cancer-associated antigens (CAAs), which in theory could treat a large number of tumours.
The global Common Cancer-associated Antigens (CAAs) Vaccine market size is expected to reach US$ 724.9 million by 2029, growing at a CAGR of 6.0% from 2023 to 2029. The market is mainly driven by the significant applications of Common Cancer-associated Antigens (CAAs) Vaccine in various end use industries. The expanding demands from the Pediatrics and Adults, are propelling Common Cancer-associated Antigens (CAAs) Vaccine market. Tecemotide, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Astuprotimut-R segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Common Cancer-associated Antigens (CAAs) Vaccine, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Common Cancer-associated Antigens (CAAs) Vaccine market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Common Cancer-associated Antigens (CAAs) Vaccine market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Common Cancer-associated Antigens (CAAs) Vaccine sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Common Cancer-associated Antigens (CAAs) Vaccine covered in this report include Seattle Genetics, Merck Serono, Merck KGaA, GlaxoSmithKline, KAEL-GemVax, SELLAS Life Sciences, Celldex and Immatics Biotechnologies, etc.
The global Common Cancer-associated Antigens (CAAs) Vaccine market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Seattle Genetics
Merck Serono
Merck KGaA
GlaxoSmithKline
KAEL-GemVax
SELLAS Life Sciences
Celldex
Immatics Biotechnologies
Global Common Cancer-associated Antigens (CAAs) Vaccine market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Common Cancer-associated Antigens (CAAs) Vaccine market, Segment by Type:
Tecemotide
Astuprotimut-R
Tertomotide
Nelipepimut-S
Others
Global Common Cancer-associated Antigens (CAAs) Vaccine market, by Application
Pediatrics
Adults
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Common Cancer-associated Antigens (CAAs) Vaccine companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Perhaps a more cost-effective option lies in developing vaccines using common cancer-associated antigens (CAAs), which in theory could treat a large number of tumours.
The global Common Cancer-associated Antigens (CAAs) Vaccine market size is expected to reach US$ 724.9 million by 2029, growing at a CAGR of 6.0% from 2023 to 2029. The market is mainly driven by the significant applications of Common Cancer-associated Antigens (CAAs) Vaccine in various end use industries. The expanding demands from the Pediatrics and Adults, are propelling Common Cancer-associated Antigens (CAAs) Vaccine market. Tecemotide, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Astuprotimut-R segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Common Cancer-associated Antigens (CAAs) Vaccine, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Common Cancer-associated Antigens (CAAs) Vaccine market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Common Cancer-associated Antigens (CAAs) Vaccine market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Common Cancer-associated Antigens (CAAs) Vaccine sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Common Cancer-associated Antigens (CAAs) Vaccine covered in this report include Seattle Genetics, Merck Serono, Merck KGaA, GlaxoSmithKline, KAEL-GemVax, SELLAS Life Sciences, Celldex and Immatics Biotechnologies, etc.
The global Common Cancer-associated Antigens (CAAs) Vaccine market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Seattle Genetics
Merck Serono
Merck KGaA
GlaxoSmithKline
KAEL-GemVax
SELLAS Life Sciences
Celldex
Immatics Biotechnologies
Global Common Cancer-associated Antigens (CAAs) Vaccine market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Common Cancer-associated Antigens (CAAs) Vaccine market, Segment by Type:
Tecemotide
Astuprotimut-R
Tertomotide
Nelipepimut-S
Others
Global Common Cancer-associated Antigens (CAAs) Vaccine market, by Application
Pediatrics
Adults
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Common Cancer-associated Antigens (CAAs) Vaccine companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Common Cancer-associated Antigens (CAAs) Vaccine
1.1 Common Cancer-associated Antigens (CAAs) Vaccine Market Overview
1.1.1 Common Cancer-associated Antigens (CAAs) Vaccine Product Scope
1.1.2 Common Cancer-associated Antigens (CAAs) Vaccine Market Status and Outlook
1.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Region (2018-2029)
1.4 Global Common Cancer-associated Antigens (CAAs) Vaccine Historic Market Size by Region (2018-2023)
1.5 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Common Cancer-associated Antigens (CAAs) Vaccine Market Size (2018-2029)
1.6.1 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size (2018-2029)
1.6.2 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size (2018-2029)
1.6.3 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size (2018-2029)
1.6.4 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size (2018-2029)
1.6.5 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size (2018-2029)
2 Common Cancer-associated Antigens (CAAs) Vaccine Market by Type
2.1 Introduction
2.1.1 Tecemotide
2.1.2 Astuprotimut-R
2.1.3 Tertomotide
2.1.4 Nelipepimut-S
2.1.5 Others
2.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Historic Market Size by Type (2018-2023)
2.2.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Common Cancer-associated Antigens (CAAs) Vaccine Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Common Cancer-associated Antigens (CAAs) Vaccine Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Common Cancer-associated Antigens (CAAs) Vaccine Revenue Breakdown by Type (2018-2029)
3 Common Cancer-associated Antigens (CAAs) Vaccine Market Overview by Application
3.1 Introduction
3.1.1 Pediatrics
3.1.2 Adults
3.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Historic Market Size by Application (2018-2023)
3.2.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Common Cancer-associated Antigens (CAAs) Vaccine Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Common Cancer-associated Antigens (CAAs) Vaccine Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Common Cancer-associated Antigens (CAAs) Vaccine Revenue Breakdown by Application (2018-2029)
4 Common Cancer-associated Antigens (CAAs) Vaccine Competition Analysis by Players
4.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Common Cancer-associated Antigens (CAAs) Vaccine as of 2022)
4.3 Date of Key Players Enter into Common Cancer-associated Antigens (CAAs) Vaccine Market
4.4 Global Top Players Common Cancer-associated Antigens (CAAs) Vaccine Headquarters and Area Served
4.5 Key Players Common Cancer-associated Antigens (CAAs) Vaccine Product Solution and Service
4.6 Competitive Status
4.6.1 Common Cancer-associated Antigens (CAAs) Vaccine Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Seattle Genetics
5.1.1 Seattle Genetics Profile
5.1.2 Seattle Genetics Main Business
5.1.3 Seattle Genetics Common Cancer-associated Antigens (CAAs) Vaccine Products, Services and Solutions
5.1.4 Seattle Genetics Common Cancer-associated Antigens (CAAs) Vaccine Revenue (US$ Million) & (2018-2023)
5.1.5 Seattle Genetics Recent Developments
5.2 Merck Serono
5.2.1 Merck Serono Profile
5.2.2 Merck Serono Main Business
5.2.3 Merck Serono Common Cancer-associated Antigens (CAAs) Vaccine Products, Services and Solutions
5.2.4 Merck Serono Common Cancer-associated Antigens (CAAs) Vaccine Revenue (US$ Million) & (2018-2023)
5.2.5 Merck Serono Recent Developments
5.3 Merck KGaA
5.3.1 Merck KGaA Profile
5.3.2 Merck KGaA Main Business
5.3.3 Merck KGaA Common Cancer-associated Antigens (CAAs) Vaccine Products, Services and Solutions
5.3.4 Merck KGaA Common Cancer-associated Antigens (CAAs) Vaccine Revenue (US$ Million) & (2018-2023)
5.3.5 GlaxoSmithKline Recent Developments
5.4 GlaxoSmithKline
5.4.1 GlaxoSmithKline Profile
5.4.2 GlaxoSmithKline Main Business
5.4.3 GlaxoSmithKline Common Cancer-associated Antigens (CAAs) Vaccine Products, Services and Solutions
5.4.4 GlaxoSmithKline Common Cancer-associated Antigens (CAAs) Vaccine Revenue (US$ Million) & (2018-2023)
5.4.5 GlaxoSmithKline Recent Developments
5.5 KAEL-GemVax
5.5.1 KAEL-GemVax Profile
5.5.2 KAEL-GemVax Main Business
5.5.3 KAEL-GemVax Common Cancer-associated Antigens (CAAs) Vaccine Products, Services and Solutions
5.5.4 KAEL-GemVax Common Cancer-associated Antigens (CAAs) Vaccine Revenue (US$ Million) & (2018-2023)
5.5.5 KAEL-GemVax Recent Developments
5.6 SELLAS Life Sciences
5.6.1 SELLAS Life Sciences Profile
5.6.2 SELLAS Life Sciences Main Business
5.6.3 SELLAS Life Sciences Common Cancer-associated Antigens (CAAs) Vaccine Products, Services and Solutions
5.6.4 SELLAS Life Sciences Common Cancer-associated Antigens (CAAs) Vaccine Revenue (US$ Million) & (2018-2023)
5.6.5 SELLAS Life Sciences Recent Developments
5.7 Celldex
5.7.1 Celldex Profile
5.7.2 Celldex Main Business
5.7.3 Celldex Common Cancer-associated Antigens (CAAs) Vaccine Products, Services and Solutions
5.7.4 Celldex Common Cancer-associated Antigens (CAAs) Vaccine Revenue (US$ Million) & (2018-2023)
5.7.5 Celldex Recent Developments
5.8 Immatics Biotechnologies
5.8.1 Immatics Biotechnologies Profile
5.8.2 Immatics Biotechnologies Main Business
5.8.3 Immatics Biotechnologies Common Cancer-associated Antigens (CAAs) Vaccine Products, Services and Solutions
5.8.4 Immatics Biotechnologies Common Cancer-associated Antigens (CAAs) Vaccine Revenue (US$ Million) & (2018-2023)
5.8.5 Immatics Biotechnologies Recent Developments
6 North America
6.1 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Common Cancer-associated Antigens (CAAs) Vaccine Market Dynamics
11.1 Common Cancer-associated Antigens (CAAs) Vaccine Industry Trends
11.2 Common Cancer-associated Antigens (CAAs) Vaccine Market Drivers
11.3 Common Cancer-associated Antigens (CAAs) Vaccine Market Challenges
11.4 Common Cancer-associated Antigens (CAAs) Vaccine Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
